Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

NCT02034110 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

206

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: Dabrafenib
DRUG: Trametinib

Sponsor

Novartis Pharmaceuticals